CommercialPrior AuthMedium impact
Pulmonary Arterial Hypertension
Blue Cross & Blue Shield of Mississippi·MS · Cardiology, Pulmonology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy for pulmonary arterial hypertension medications, requiring prior authorization for 18 different PAH drugs including Adcirca, Revatio, Flolan, and others. The policy establishes specific clinical criteria based on WHO functional class, hemodynamic measurements, and therapy combinations that must be documented for approval.
Action Required
Immediately: Billing team must verify prior authorization requirements for all PAH medications listed in policy before submitting claims. Ensure providers document WHO functional class, right heart catheterization results (mPAP ≥20mmHg, PCWP <15mmHg, PVR ≥3 Wood units), and specialist consultation in medical records. Perform formulary drug search on patient's member ID before prescribing. Claims for PAH medications without proper prior authorization will be denied.